240 related articles for article (PubMed ID: 15853709)
1. The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases.
Augustyns K; Van der Veken P; Senten K; Haemers A
Curr Med Chem; 2005; 12(8):971-98. PubMed ID: 15853709
[TBL] [Abstract][Full Text] [Related]
2. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII.
Leiting B; Pryor KD; Wu JK; Marsilio F; Patel RA; Craik CS; Ellman JA; Cummings RT; Thornberry NA
Biochem J; 2003 Apr; 371(Pt 2):525-32. PubMed ID: 12529175
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.
Lankas GR; Leiting B; Roy RS; Eiermann GJ; Beconi MG; Biftu T; Chan CC; Edmondson S; Feeney WP; He H; Ippolito DE; Kim D; Lyons KA; Ok HO; Patel RA; Petrov AN; Pryor KA; Qian X; Reigle L; Woods A; Wu JK; Zaller D; Zhang X; Zhu L; Weber AE; Thornberry NA
Diabetes; 2005 Oct; 54(10):2988-94. PubMed ID: 16186403
[TBL] [Abstract][Full Text] [Related]
4. Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein.
Chen SJ; Jiaang WT
Curr Top Med Chem; 2011; 11(12):1447-63. PubMed ID: 21510839
[TBL] [Abstract][Full Text] [Related]
5. The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.
Augustyns K; Bal G; Thonus G; Belyaev A; Zhang XM; Bollaert W; Lambeir AM; Durinx C; Goossens F; Haemers A
Curr Med Chem; 1999 Apr; 6(4):311-27. PubMed ID: 10101215
[TBL] [Abstract][Full Text] [Related]
6. The structural comparison of the bacterial PepX and human DPP-IV reveals sites for the design of inhibitors of PepX activity.
Rigolet P; Xi XG; Rety S; Chich JF
FEBS J; 2005 Apr; 272(8):2050-9. PubMed ID: 15819895
[TBL] [Abstract][Full Text] [Related]
7. Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains.
Tiruppathi C; Miyamoto Y; Ganapathy V; Roesel RA; Whitford GM; Leibach FH
J Biol Chem; 1990 Jan; 265(3):1476-83. PubMed ID: 1967253
[TBL] [Abstract][Full Text] [Related]
8. Rapid parallel synthesis of dipeptide diphenyl phosphonate esters as inhibitors of dipeptidyl peptidases.
Senten K; Daniëls L; Van der Veken P; De Meester I; Lambeir AM; Scharpé S; Haemers A; Augustyns K
J Comb Chem; 2003; 5(3):336-44. PubMed ID: 12739951
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase 8/9-like activity in human leukocytes.
Maes MB; Dubois V; Brandt I; Lambeir AM; Van der Veken P; Augustyns K; Cheng JD; Chen X; Scharpé S; De Meester I
J Leukoc Biol; 2007 May; 81(5):1252-7. PubMed ID: 17287297
[TBL] [Abstract][Full Text] [Related]
10. Identification of serine 624, aspartic acid 702, and histidine 734 as the catalytic triad residues of mouse dipeptidyl-peptidase IV (CD26). A member of a novel family of nonclassical serine hydrolases.
David F; Bernard AM; Pierres M; Marguet D
J Biol Chem; 1993 Aug; 268(23):17247-52. PubMed ID: 8102366
[TBL] [Abstract][Full Text] [Related]
11. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors.
Demuth HU; McIntosh CH; Pederson RA
Biochim Biophys Acta; 2005 Aug; 1751(1):33-44. PubMed ID: 15978877
[TBL] [Abstract][Full Text] [Related]
12. Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery.
Van der Veken P; Haemers A; Augustyns K
Curr Top Med Chem; 2007; 7(6):621-35. PubMed ID: 17352682
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase IV: development, design, synthesis and biological evaluation of inhibitors.
Borloo M; De Meester I
Verh K Acad Geneeskd Belg; 1994; 56(1):57-88. PubMed ID: 7911611
[TBL] [Abstract][Full Text] [Related]
14. Fluoro-olefins as peptidomimetic inhibitors of dipeptidyl peptidases.
Van der Veken P; Senten K; Kertèsz I; De Meester I; Lambeir AM; Maes MB; Scharpé S; Haemers A; Augustyns K
J Med Chem; 2005 Mar; 48(6):1768-80. PubMed ID: 15771423
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
Kirby M; Yu DM; O'Connor S; Gorrell MD
Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix.
Piazza GA; Callanan HM; Mowery J; Hixson DC
Biochem J; 1989 Aug; 262(1):327-34. PubMed ID: 2573346
[TBL] [Abstract][Full Text] [Related]
17. Development of potent and selective dipeptidyl peptidase II inhibitors.
Senten K; Van der Veken P; Bal G; De Meester I; Lambeir AM; Scharpé S; Bauvois B; Haemers A; Augustyns K
Bioorg Med Chem Lett; 2002 Oct; 12(20):2825-8. PubMed ID: 12270155
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning and biochemical characterization of Xaa-Pro dipeptidyl-peptidase from Streptococcus mutans and its inhibition by anti-human DPP IV drugs.
De A; Lupidi G; Petrelli D; Vitali LA
FEMS Microbiol Lett; 2016 May; 363(9):. PubMed ID: 27010012
[TBL] [Abstract][Full Text] [Related]
19. 4-Substituted boro-proline dipeptides: synthesis, characterization, and dipeptidyl peptidase IV, 8, and 9 activities.
Wu W; Liu Y; Milo LJ; Shu Y; Zhao P; Li Y; Woznica I; Yu G; Sanford DG; Zhou Y; Poplawski SE; Connolly BA; Sudmeier JL; Bachovchin WW; Lai JH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5536-40. PubMed ID: 22853995
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).
Brandt I; Joossens J; Chen X; Maes MB; Scharpé S; De Meester I; Lambeir AM
Biochem Pharmacol; 2005 Jul; 70(1):134-43. PubMed ID: 15907807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
